The ectoenzyme E-NPP3 (CD203c) has recently been identified as a novel activation-linked cell surface antigen on basophils. In the present study, we examined expression of CD203c on normal mast cells (MC) and bone marrow (bm) MC derived from 85 patients with systemic mastocytosis (SM), including cases with indolent SM (ISM, n=72), SM with associated clonal hematologic non-MC-lineage disease (SM-AHNMD, n=6), aggressive SM (ASM, n=3), and mast cell leukemia (MCL, n=4). Surface expression of CD203c was analyzed by multicolor flow cytometry. In patients with SM, bm MC expressed significantly higher amounts of CD203c compared to normal bm MC (median MFI in controls: 260 versus median MFI in SM: 516, p<0.05). Slightly lower amounts of CD203c were detected on MC in SM-AHNMD and ASM compared to ISM. To demonstrate CD203c expression in MC at the mRNA level, neoplastic MC were highly enriched by cell sorting, and were found to express CD203c mRNA in RT-PCR analysis. Cross-linking of the IgE receptor on MC resulted in a substantial upregulation of CD203c, whereas the KIT-ligand stem cell factor (SCF) showed no significant effects. In conclusion, CD203c is a novel activation-linked surface antigen on MC that is upregulated in response to IgE receptor cross-linking and is overexpressed on neoplastic MC in patients with SM.
variants of SM have been described (1) (2) (3) (4) (5) (6) (13) (14) . The WHO classification defines 4 distinct subtypes of SM: indolent SM (ISM), SM with an associated hematologic clonal non-MC-lineage disease (SM-AHNMO), aggressive SM (ASM), and MC leukemia (MCL) (13) (14) . The clinical course and prognosis vary among patients with different categories of SM (1) (2) (3) (4) (5) (6) (13) (14) .
A number of recent studies have shown that distinct cell surface antigens are aberrantly expressed (overexpressed) on neoplastic MC in SM compared to normal MC (15) (16) (17) (18) (19) . These antigens include LFA-2 (C02), the IL-2 receptor alpha chain (C025), complement receptor-I, CRI (CD35), LAMP-3 (C063), and the C5a receptor (C088) (14) (15) (16) (17) (18) . Several of these molecules serve as disease-related diagnostic parameters in SM (13) (14) . Most significantly, C02 and C025 are almost exclusively expressed on neoplastic MC in SM, but not on nonnal MC (15) (16) . Therefore, these two markers are employed as minor SM criteria in the WHO classification of mastocytosis (13) (14) . Other markers, such as C063, C069, or C088, are also markedly overexpressed on MC in SM compared to normal MC, and thus may be helpful in confirming the diagnosis of SM (16) (17) . An interesting aspect is that some of these molecules (such as C02) may also contribute to the abnormal distribution (clusterformation) and function of neoplastic MC in SM (17) (18) (19) . Another remarkable aspect is that several of these antigens, such as C063, also increase in expression on blood basophils or MC after crosslinking of the high affinity IgE receptor (FCERI) (19) (20) .
The ectonucleotide pyrophosphatase / phosphodiesterases 3 ectoenzyme (E-NPP3 = C0203c) has recently been identified as an activation-linked cell surface antigen that is expressed on blood basophils and their progenitors, and less abundantly on normal tissue MC (21) (22) (23) (24) (25) . In response to cross-linking of IgE receptors, the surface levels of CD203c on basophils increase (21, 23) . However, to date, little is known about the regulation of expression of C0203c on MC.
In this study, we examined expression of CD203c on normal MC, and on neoplastic MC in patients with various categories of SM, and asked whether cross-linking of IgE receptors on normal/neoplastic MC is followed by upregulation ofC0203c.
MATERIALS ANO METHODS

Monoclonal antibodies (mAb) and other reagents
The allophycocyanin (APC)-conjugated mAb 104020 I (CD 117), the phycoerythrin (PE)-Iabeled mAb 97A6 (CD203c), fluorescein isothiocyanate (FITC)labeled mAb CLB-granl2 (CD63), as well as the anti-IgE mAb EI24.2.8 (De2), were purchased from Immunotech (Marseille, France), and the PE-Iabeled mAb 581 (CD34) and the peridinin chlorophyll protein (PerCP)-conjugated mAb 201 (CD45) from Becton Dickinson Biosciences (San Jose, CA). Collagenase type II was purchased from Worthington Biochemical Cooperation (Lakewood, NJ), RPMI 1640 medium, fetal calf serum (FCS) from PAA laboratories (Linz, Austria), Iscove's modified Dulbecco s medium (IMDM) from Gibco Life Technologies (Gaithersburg, MD), rh interleukin-4 (IL-4) and rh IL-6 from Peprotech (Rocky Hill, NJ), rh IL-3 from Novartis (Vienna, Austria), and rh stem cell factor (SCF) from Strathmann Biotech (Hannover, Germany), NIP(5)-BSA was purchased from Biosearch Technologies (Novato, CA), a chimeric human NIP-specific IgE (clone Jw8.1) from AbO Serotec (DUsseldorf, Germany), Stem Span serum-free medium (SFM) from Stem Cell Technologies (CellSystems, St Katharinen, Germany), and the CD 133 Microbead Kit from Miltenyi Biotec (Bergisch Gladbach, Germany). One liter Mg/Ca-free Tyrodes buffer contained 0.2 g KCI, 0.05 g NaH 2 P0 4.Hp, 8.0 g NaCI and I g glucose.
Patients and isolation ofM'C
Bone marrow (bm) MC were examined in 85 patients with SM (diagnostic bm examination), 4 cases with cutaneous mastocytosis (subtype: urticaria pigmentosa, UP), 62 control patients with various clonal non-MC hematologic disorders (vHD: M. Hodgkin, n=5; acute myeloid leukemia, n=5; chronic lymphocytic leukemia, n=8; non-Hodgkin's lymphoma: n= 17; multiple myeloma, n=5; myelodysplastic syndromes, n=5; monoclonal gammopathy ofundetennined significance, n=7; other clonal disorders; n=IO), and 38 patients with nonnaIlreactive bm. Bone marrow aspirates were obtained from the iliac crest and collected in EDTAcontaining or heparin-containing syringes after informed consent was obtained. Patients with SM were diagnosed and classified according to WHO criteria: ISM: n=72, SM-AHNMD: n=6, ASM: n=3, MCL: n=4. The patients' characteristics are shown in Table I . Lung tissue was obtained from two patients with bronchiogenic carcinoma. Informed consent was obtained in each patient. Lung specimens were placed in Tyrodes buffer immediately after resection. MC were prepared and enriched from lung specimens using collagenase type II as described previously (24, 26) . For PCR analysis, neoplastic MC were purified to homogeneity by Ficoll density centrifugation and flow cytometry on a high speed sorter (FACS VANTAGE, Becton Dickinson) using antibodies against COll7 and CD34, as described (27) . In all three samples, the purity ofMC was >98%.
Culture ofHMC-l cells
The MC cell line HMC-l (28), derived from a patient with MCL, was kindly provided by Dr. Joseph H.
Butterfield (Mayo Clinic, Rochester, MN). HMC-l cells were grown in IMDM supplemented with 10% FCS, Lglutamine, and antibiotics at 37°C and 5% CO 2 , HMC-l cells were periodically checked for i) the presence of metachromatic granules, ii) expression of KIT, and iii) the down-modulating effect ofIL-4 (100 V/ml, 48 hours) on KIT expression (29) .
Culture ofcord blood-derived human mast cells
Normal MC were generated in cord blood (CB) cell cultures following an established protocol (30) . In brief, CD133+ progenitors were isolated from CB MNC using CD 133+ magnetic microbeads and the QuadroMACS magnetic separator according to the manufacturer's instructions (Miltenyi Biotec). The purity ofisolated CD 133+ cells amounted to >97%. Isolated cells (0.5 x 106/ ml) were cultured in 6-well plates (Costar, Cambridge, MA) in Stem Span serum-free medium (SFM) (Stem Cell Technologies CellSystems, St Katharinen, Germany) supplemented with SCF (100 ng/ml), IL-6 (100 ng/ml), and IL-3 (30 ng/ml) for two weeks, and thereafter in medium containing SCF and IL-6 without IL-3 (30) . After 4 weeks, RPMI 1640 medium containing 10% FCS was used instead of SFM. Cytokines were replaced weekly. After 7 weeks, 70-80% of cells were mature MC, as evidenced by Wright-Giemsa staining and tryptase staining.
Stimulation ofMC through IgE receptor or SCF receptor
In two lung cell suspensions and 3 bm aspirates (crude heparinized aspirates, ISM), primary tissue MC were incubated with either control medium or the anti-IgE antibody E.124.2.8 (1 ug/ml) at 37°C for 15-30 minutes, or with either control medium or SCF (100 ng/ml) at 37°C for 90 minutes. Cultured cord blood-derived MC were incubated with human IgE (Jw8) at 10 ug/rnl together with IL-4 (25 ng/ml) overnight prior to IgE receptor crosslinking. MC were challenged with NIP(5)-BSA (100 ng/ml) in phenolred-free RPMI 1640 medium plus 0.1% BSA for various time periods (0-90 minutes) at 37°C. After incubation, cord blood-derived MC were subjected to antibody-staining and single color flow cytornetry performed using PE-labeled antibodies against CD63 and/ or CD203c. In case of lung MC and bm MC, multi color flow cytometry was performed (see below).
Multicolor flow cytometry
For detection and examination of MC in dispersed lung cell suspensions or bm aspirates, a multicolor staining technique was applied using fluorochromelabeled antibodies against CD34, CD45, CD63, CD117, and CD203c. MC were identified by their typical forward! sideward light scatter characteristics and their typical phenotype (CD45+/COlI7+/CD34-) as reported (31) . Expression of CD63 and CD203c on MC was quantified by calculating mean fluorescence intensity (MFI).
RT-PCR
RT-PCR analysis was performed on highly enriched neoplastic MC (two patients with MCL and one with MC sarcoma), HMC-l cells, and A431 cells (epithelial control cell line) according to an established protocol (27, 32) . Total RNA was isolated using Trizol" (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. RT-PCR reactions were performed with the Protoscript First Strand eDNA Synthesis kit (New England Biolabs, Beverly, MA) using 1 ug total RNA in a 50 ul, reaction volume. PCR conditions were as follows: initial denaturation at 94°C for 40 seconds, annealing at 58°C for 40 seconds, polymerization at nocfor 40 seconds (35 cycles), and terminal extension at noc for 10 minutes. The products were resolved in 1% agarose gels containing 0.5 ug/ml, ethidium bromide. The following primer pairs were used: CD203c: 5'-AGA TGC TAA ATC TCA CCC AAG A -3' (forward), 5'-GAG GGA TGA TAAAGG GTA GGAC -3' (reverse), PCR product 200 bp; 13-Actin: 5'-GAC GGC CAG GTC ATC ACT AT -3' (forward), 5'-AGG GAG ACCAAAGCC TTCAT -3' (reverse), PCR product 1000 bp.
Statistics
The Kruskal-Wallis test was applied to determine the level of significance in differences of CD203c expression on MC between the various groups of patients with SM. Differences were considered to be significant when the p value was <0.05.
Comparisons of two independent groups were made according the Mann-U test. For multiple comparisons, statistical analysis was adjusted according to the method of Bonferroni.
RESULTS
MC in patients with SM express elevated levels of CD203c
In patients with SM (n=85), the median level of CD203c (MFI) was found to be significantly higher P <0.05 1) . In four patients with cutaneous mastocytosis (UP), the levels of CD203c were found to be within the 'normal' range (normal/reactive bm). Also, in patients with various non-MC-lineage hematologic disorders (vHD), including Non-Hodgkin's lymphomas, the levels of CD203c expressed on bm MC were found to be in the same range as CD203c levels on MC in normal/reactive bm (MFI in vHD: 245, p>0.05) (Fig. I) .
MFI CD203c
Expression ojCD203c in various categories ojSM
In each category of SM, the levels of CD203c expressed on bm MC varied from donor to donor. Fig. 2 . Overall, no statistically significant differences among the subgroups of SM concerning expression of CD203c on MC were found. However, it was found that patients with ISM display a slightly higher median CD203c level on MC compared to patients with ASM or SM-AHNMD (Table II) . The highest CD203c MFI value was detected in a patient with MCL ( Fig. 2D) . 
. Expression of CD203c on mast cells (MC) in patients with mastocytosis with or without anaphylaxis. Expression of CD203c on bone marrow MC was quantified by multicolor flow cytometry as described in the text, and was expressed as mean fluorescence intensity (MFI) in patients with indolent systemic mastocytosis (ISM) and patients with ISM complicated by severe recurrent episodes of anaphylaxis (ISMs.). Patients were investigated in symptom-free intervals. Results show the mean fluorescence intensity (MFI) for CD203c expression in each donor (dot plots; left panels) as well as the range covering the 25/ h to 75/ h percentile of CD203c expression (box) together with median values (central horizontal line in each box) and mean values (small central rectangles in each box). As visible, expression of CD203c did not differ significantly when comparing the two cohorts ofpatients (SM versus SMsJ' p>O. 05).
Correlation between CD203c expression and previous anaphylaxis-episodes
In a next step, we compared CD203c levels on bm MC in ISM patients with recurrent anaphylaxis (ISMsv> in their symptom-free interval with that found in ISM patients without anaphylaxis. As visible in Fig. 3 , no differences in expression of CD203c on MC were found between these two groups ofpatients (p>O.05). These data suggest that an elevated level of CD203c cannot predict the occurrence or frequency of anaphylactic episodes in patients with SM.
Correlation between expression of CD203c and expression ofother cell surface antigens in bm MC
In line with previous studies (16) , neoplastic MC in SM were found to display higher levels of CD63
Fig. 4. Expression of CD117 on mast cells (MC) in patients with SM Expression ofCD117 on bone marrow MC, determined by multicolor flow cytometry, in various groups ofdonors, including normal/reactive bone marrow (co, n=38), patients with various hematologic non-MC lineage disorders (vHD, n=62), patients with systemic mastocytosis (SM, n=85), and patients with cutaneous mastocytosis (urticaria pigmentosa, Up, n=4). Results show the mean fluorescence intensity (MFI) for CD117/ KIT expression on MC in each donor (left panels) as well as the range covering the 25/ h to 75/ h percentile ofCD1l7/ KIT expression (box) together with median values (central horizontal line in each box) and mean values (small central rectangles in each box).
compared to CD63 levels on MC in normal/reactive bm (not shown). We were also able to confirm that the median levels of CD 117 on bm MC are significantly lower in SM patients compared to normal/reactive bm (p<O.05) or patients with vHD (p<O.05) ( Fig.  4 , Table II ). In the four patients with cutaneous mastocytosis (UP), the levels of CD 117 were found to be within the 'normal' range. No significant correlation between expression of CD203c and CD63 on MC and no correlation between CD203c expression and expression of CD117 on MC was found in the SM patients studied. 
Detection of CD203c mRNA in neoplastic mast cells
Fig. 6. IgE-receptor cross-linkage on mast cells (MC) is associated with upregulation of CD203c expression. A) Neoplastic MC in heparinized bone marrow samples obtainedfrom patients with indolent systemic mastocytosis (n=3) were incubated with control buffer (co) or with an anti-IgE antibody (l ug/ml) at 37°C for 15-30 minutes. Then, cells were washed and examined for expression of CD63 (open bars) and expression ofCD203c (black bars) by multicolor flow cytometry. The figure shows the mean fluorescence intensities (MFI) obtained with CDlJ 7+ MC and antibodies to CD63 and CD203c. Results represent the mean±S.D. from three donors. B) Isolated lung MC were incubated in control buffer (co), an anti-1gE antibody (l ug/ml; 30 minutes), or recombinant SCF (l00 ng/ml; 90 minutes) at 37°C. After incubation, cells were washed and analyzedfor expression of CD63 (open bars) and expression of CD203c (black bars) by multicolor flow cytometry. Results represent the mean fluorescence intensities (MFI) obtained in one donor. C, D) Cord blood eel/-derived cultured human MC were incubated with human IgE (Jw8) together with IL-4 (25 ng/ml) overnight. Then, cells were challenged with the specific antigen (l0 ug/ml) for various time periods as indicated and then were examinedfor expression ofCD203c (C) and CD63 (D) by flow cytometry. Results are expressed as meanfluorescence intensity (MFI) and show the mean.di.D. from three experiments. At all time points studied, the increase in CD63 and CD203c on cultured mast cells was significant when compared to unstimulated cells (p<0.05).
resulted in upregulation of CD203c ( Fig. 6C ) and in upregulation of CD63 on MC (Fig. 6D) . The effects of IgE-dependent activation of MC on expression of CD203c and CD63 were time-dependent. In the case of CD203c, maximum upregulation was already observed after 15-30 minutes (Fig. 6C) 
IgE-receptor cross-linkage on MC is associated with upregulation ofCD203c
A number of recent data suggest that the levels of CD203c on human basophils increase substantially after cross linkage of IgE-binding sites (21, 23) . In this study, normal lung MC and neoplastic MC were exposed to an anti-IgE antibody or SCF before being analyzed for expression of CD203c. In these experiments, the anti-IgE antibody was found to promote expression of CD203c on bm MC in all three patients with ISM analyzed (Fig. 6A) , and the same result was obtained with isolated lung MC (Fig. 6B) . By contrast, exposure of MC to SCF did not result in an increase in expression of CD203c. We also extended our studies to cultured cord blood cell derived human MC and to an antigen challenge-assay. As expected, cross-linking of the IgE receptor on these cells by exposing to IgE and then to the specific antigen (NIP(5)-BSA, 100 ng/ml) MC leukemia cell line HMC-l, known to express CD203c (19, 24) , was used as a positive control. As visible in Fig. 5 , purified MC derived from patients with MCL or from MC sarcoma as well as HMC-l cells, were found to display CD203c mRNA in our RT-PCR experiments. These results support the notion that neoplastic MC synthesize and express CD203c in a constitutive manner. ---------------------------------------------------------------------------------------------------------- in the case of CD63, a further increase in expression was seen in activated MC over time (Fig. 6D ).
--------------------------------------------------------------------------------------------------------------
DISCUSSION
The ectoenzyme E-NPP3 (CD203c) has recently been identified as a novel activation-linked surface antigen that is expressed abundantly in normal blood basophils and is upregulated in reponse to cross-linking ofIgE-binding sites (21) (22) (23) . It has also been described that CD203c is less abundantly but clearly expressed on human tissue MC (21, 24) . In the present study, we provide evidence that neoplastic bm MC in SM express higher levels of CD203c when compared to normal bm MC, and that the levels of CD203c expressed on normal or neoplastic MC increase substantially after exposure to an anti-IgE antibody.
Abnormal expression of cell surface antigens on MC is a typical feature in SM (13) (14) (15) (16) (17) (18) . In particular, several different cell surface membrane antigens are aberrantly expressed or are overexpressed on neoplastic MC compared to normal MC. Among others, these antigens include CD2, CD25, CD63, CD69, and CD88 (13) (14) (15) (16) (17) (18) . Based on this notion, the flow cytometric evaluation of bm MC has become an important diagnostic approach (and even WHO criterion) in suspected SM (13-14, 31, 33) . In the current study, we provide evidence that the ectoenzyme CD203c is also overexpressed on neoplastic bm MC in SM compared to normal MC.
A number of MC surface antigens have been developed as diagnostic markers, as these antigens are clearly upregulated in SM (15) (16) (17) (18) (19) . However, when considering CD203c as a potential diagnostic parameter, there are several limitations one has to consider. First, CD203c may also increase on MC in allergic patients, especially after allergen-contact (21, 23) . More importantly, however, the levels of CD203c on bm MC in SM vary greatly from donor to donor, and many patients with SM were found to display 'normal' levels of CD203c on their MC when compared to controls. All in all, CD203c per se may not be an ideal diagnostic parameter, but when elevated, may be employed as co-variable in suspected SM.
Another important aspect was that CD203c levels are somewhat higher in a group ofpatients with ISM as compared to patients with advanced SM, like ASM or SM-AHNMD. On the other hand, the highest CD203c levels (MF!) were found in a patient with MCL. The biochemical basis for the differential expression of CD203c on SM in various (sub) groups of patients with SM remains unknown. One explanation could be that in some patients, MC are in an activated state and thus express higher levels of CD203c. However, when comparing patients with and without anaphylaxis in their case history, no differences in expression of CD203c on MC were seen. An alternative explanation would be that the expression of CD203c correlates with a distinct stage of differentiationor maturation of neoplastic Me.
Severe anaphylaxis is a major problem in a group of patients with SM (2-6). Anaphylactic reactions may occur more or less frequently, or may not occur at all in patients with SM. Thus, even in patients without any mediator-related symptoms, one cannot exclude anaphylaxis for the future with certainty. Therefore, it would be of interest to establish a prognostic marker that could assist in the prediction of anaphylactic events in patients with SM. In the current study, we asked whether there is an association between baseline CD203c levels in the symptom-free interval and the occurrence of anaphylaxis. However, as mentioned above no such correlation was found. On the other hand CD63 and CD203c may well be employed as markers of allergic reactions in SM as these markers should increase rapidly on basophils (21, 23) and MC (see below) after cell activation.
Indeed, recent data have shown that cross-linking of IgE receptors on basophils results in upregulation ofCD203c (21, 23) . Moreover, in the present study, we were able to show that activation of MC through the IgE receptor is also followed by an increased expression of CD203c. Interestingly, the effect of the anti-IgE antibody was seen in normal lung MC as well as in neoplastic bm MC in patients with SM. This is of particular interest, as severe and sometimes fatal anaphylactic reactions are seen in patients with SM, and some of these reactions may be triggered by specific IgE and then may require specific (immuno)therapy (33) .
In summary, our data show that CD203c is constitutively overexpressed on neoplastic MC in patients with SM, and is upregulated on normal and neoplastic MC upon crosslinkage of IgE-receptors.
